The Application of Nanotechnology to Drug Delivery in Medicine

Nanoengineering: Global Approaches to Health and Safety Issues

Volumn , Issue , 2015, Pages 173-223

  McDonald, Tom O ^a   Siccardi, Marco ^a   Moss, Darren ^a   Liptrott, Neill ^a   Giardiello, Marco ^a   Rannard, Steve ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bioavailability; Future directions; Liposome; Micelle; Nanocarrier; Nanoimmunology; Nanomedicine; Nanoparticle; Nanosuspension; Oral; Parental; Pharmacokinetics; Polymer therapeutics; Solid drug nanoparticle; Targeting; Therapeutics

Indexed keywords

BIOCHEMISTRY; CLINICAL RESEARCH; ENZYME INHIBITION; FUNCTIONAL POLYMERS; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MICELLES; NANOPARTICLES; NANOSTRUCTURED MATERIALS; PHARMACOKINETICS;

BIOAVAILABILITY; DRUG NANO PARTICLES; FUTURE DIRECTIONS; NANO-SUSPENSIONS; NANOCARRIERS; NANOIMMUNOLOGY; ORAL; PARENTAL; POLYMER THERAPEUTICS; TARGETING; THERAPEUTICS;

DRUG DELIVERY;

EID: 84940038398     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-62747-6.00007-5     Document Type: Chapter

References (217)

1. http://www.nano.gov/nanotech-101/nanotechnology-facts.
2. Ramsden J.J., Julie F. The nanoscale. Nanotechnol Perceptions 2009, 5:3-25.
3. mailto:ftp://ftp.cordis.europa.eu/pub/nanotechnology/docs/nanomedicine_visionpaper.pdf.
4. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6(9):688-701.
5. Russell A.D., Path F.R.C., Sl F.R.P., Hugo W.B. Antimicrobial activity and action of silver. Prog Med Chem 1994, 31:351.
6. Marchasin S., Wallerstein R.O. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 1964, 23(3):354-358.
7. Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8(6):473-480.
8. Ringsdorf H. Hermann Staudinger and the future of polymer research jubilees-beloved occasions for cultural piety. Angew Chem Int Ed 2004, 43(9):1064-1076.
9. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8(6):2101-2141.
10. Ferrucci J.T., Stark D.D. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. Am J Roentgenol 1990, 155(5):943-950.
11. Hall J.B., Dobrovolskaia M.A., Patri A.K., McNeil S.E. Characterization of nanoparticles for therapeutics. Nanomedicine 2007, 2(6):789-803.
12. Rabinow B.E. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004, 3(9):785-796.
13. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res 2000, 17(4):397-404.
14. Junghanns J.-U.A.H., Mueller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008, 3(3):295-309.
15. Möschwitzer J.P. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 2013, 453(1):142-156.
16. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47(1):3-19.
17. McDonald T.O., Giardiello M., Martin P., Siccardi M., Liptrott N.J., Smith D., et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv Healthcare Mater 2014, 3(3):400-411.
18. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011, 22(4):492-501.
19. Webster R., Elliott V., Park B.K., Walker D., Hankin M., Taupin P. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. PEGylated protein drugs: basic science and clinical applications 2009, 127-146. Birkhäuser Basel. F. Veronese (Ed.).
20. Chipman S.D., Oldham F.B., Pezzoni G., Singer J.W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomed 2006, 1(4):375-383.
21. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2(5):347-360.
22. Navath R.S., Kurtoglu Y.E., Wang B., Kannan S., Romero R., Kannan R.M. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjugate Chem 2008, 19(12):2446-2455.
23. Zhu J., Shi X. Dendrimer-based nanodevices for targeted drug delivery applications. J Mater Chem B 2013, 1(34):4199-4211.
24. Larson N., Ghandehari H. Polymeric conjugates for drug delivery. Chem Mater 2012, 24(5):840-853.
25. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotechnol Biol Med 2010, 6(6):714-729.
26. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001, 73(2-3):137-172.
27. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30(11):592-599.
28. Kim J.-H., Emoto K., Iijima M., Nagasaki Y., Aoyagi T., Okano T., et al. Core-stabilized polymeric micelle as potential drug carrier: increased solubilization of taxol. Polym Adv Technol 1999, 10(11):647-654.
29. Patil Y.B., Toti U.S., Khdair A., Ma L., Panyam J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 2009, 30(5):859-866.
30. Akbarzadeh A., Rezaei-Sadabady R., Davaran S., Joo S., Zarghami N., Hanifehpour Y., et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013, 8(1):1-9.
31. Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J Pharm Pharmacol 2010, 62(11):1637-1645.
32. Lovelyn C., Attama A.A. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol 2011, 2.
33. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000, 50(1):161-177.
34. Sasaki Y., Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec 2010, 10(6):366-376.
35. Locatelli E., Comes Franchini M. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J Nanopart Res 2012, 14(12):1-17.
36. Nitta S.K., Numata K. Biopolymer-based nanoparticles for Drug/Gene delivery and tissue engineering. Int J Mol Sci 2013, 14(1):1629-1654.
37. Yallapu M.M., Jaggi M., Chauhan S.C. Design and engineering of nanogels for cancer treatment. Drug Discov Today 2011, 16(9-10):457-463.
38. Raemdonck K., Demeester J., De Smedt S. Advanced nanogel engineering for drug delivery. Soft Matter 2009, 5(4):707-715.
39. Nakamoto M., Hoshino Y., Miura Y. Effect of physical properties of nanogel particles on the kinetic constants of multipoint protein recognition process. Biomacromolecules 2013, 15(2):541-547.
40. Owens Iii D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307(1):93-102.
41. Schubert S., Delaney J.J.T., Schubert U.S. Nanoprecipitation and nanoformulation of polymers: from history to powerful possibilities beyond poly(lactic acid). Soft Matter 2011, 7(5):1581-1588.
42. Kazakov S., Kaholek M., Teraoka I., Levon K. UV-induced gelation on nanometer scale using liposome reactor. Macromolecules 2002, 35(5):1911-1920.
43. Lee E.S., Kim D., Youn Y.S., Oh K.T., Bae Y.H. A virus-mimetic nanogel vehicle. Angew Chem Int Ed 2008, 47(13):2418-2421.
44. Glangchai L.C., Caldorera-Moore M., Shi L., Roy K. Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. J Control Release 2008, 125(3):263-272.
45. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1(3):325-327.
46. Ling D., Hyeon T. Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small 2013, 9(9-10):1450-1466.
47. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008, 60(11):1307-1315.
48. Huang K., Ma H., Liu J., Huo S., Kumar A., Wei T., et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 2012, 6(5):4483-4493.
49. Gibson J.D., Khanal B.P., Zubarev E.R. Paclitaxel-functionalized gold nanoparticles. J Am Chem Soc 2007, 129(37):11653-11661.
50. Huang X., Qian W., El-Sayed I.H., El-Sayed M.A. The potential use of the enhanced nonlinear properties of gold nanospheres in photothermal cancer therapy. Lasers Surg Med 2007, 39(9):747-753.
51. Frenkel J., Dorfman J. Spontaneous and induced magnetisation in ferromagnetic bodies. Nature 1930, 126:274-275.
52. Blasiak B., van Veggel F.C.J.M., Tomanek B. Applications of nanoparticles for MRI Cancer diagnosis and therapy. J Nanomater 2013, 2013:12.
53. Kumar C.S.S.R., Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev 2011, 63(9):789-808.
54. Derfus A.M., von Maltzahn G., Harris T.J., Duza T., Vecchio K.S., Ruoslahti E., et al. Remotely triggered release from magnetic nanoparticles. Adv Mater 2007, 19(22):3932-3936.
55. Brazel C. Magnetothermally-responsive nanomaterials: combining magnetic nanostructures and thermally-sensitive polymers for triggered drug release. Pharm Res 2009, 26(3):644-656.
56. Schmid G. Large clusters and colloids. Metals in the embryonic state. Chem Rev 1992, 92(8):1709-1727.
57. Templeton A.C., Wuelfing W.P., Murray R.W. Monolayer-protected cluster molecules. Acc Chem Res 1999, 33(1):27-36.
58. Frens G. Controlled nucleation for regulation of particle-size in monodisperse gold suspensions. Nat Phys Sci 1973, 241(105):20-22.
59. Pedro T., María del Puerto M., Sabino V.-V., Teresita G.-C., Carlos J.S. The preparation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 2003, 36(13):R182.
60. Shah D. Fine particles: synthesis, characterization, and mechanisms of growth. J Nanopart Res 2002, 4(1-2):179. T. Sugimoto (Ed.).
61. Sharom F.J. The P-glycoprotein multidrug transporter. Essays Biochem 2011, 50(1):161-178.
62. Tuma P., Hubbard A.L. Transcytosis: crossing cellular barriers. Physiol Rev 2003, 83(3):871-932.
63. Menon G.K., Cleary G.W., Lane M.E. The structure and function of the stratum corneum. Int J Pharm 2012, 435(1):3-9.
64. Rehman K., Zulfakar M.H. Recent advances in gel technologies for topical and transdermal drug delivery. Drug Dev Ind Pharm 2014, 40(4):433-440.
65. Gide P.S., Gidwani S.K., Kothule K.U. Enhancement of transdermal penetration and bioavailability of poorly soluble acyclovir using solid lipid nanoparticles incorporated in gel cream. Indian J Pharm Sci 2013, 75(2):138-142.
66. Cappel M.J., Kreuter J. Effect of nanoparticles on transdermal drug delivery. J Microencapsul 1991, 8(3):369-374.
67. Khurana S., Jain N.K., Bedi P.M. Nanoemulsion based gel for transdermal delivery of meloxicam: physico-chemical, mechanistic investigation. Life Sci 2013, 92(6-7):383-392.
68. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007, 6(1):67-74.
69. Musante C.J., Schroeter J.D., Rosati J.A., Crowder T.M., Hickey A.J., Martonen T.B. Factors affecting the deposition of inhaled porous drug particles. J Pharm Sci 2002, 91(7):1590-1600.
70. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
71. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998, 95(8):4607-4612.
72. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65(1-2):271-284.
73. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006, 11(17-18):812-818.
74. Murphy G.F., Brody A.R., Craighead J.E. Monocyte migration across pulmonary membranes in mice infected with cytomegalovirus. Exp Mol Pathol 1975, 22(1):35-44.
75. Lameijer M.A., Tang J., Nahrendorf M., Beelen R.H., Mulder W.J. Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn 2013, 13(6):567-580.
76. Raso V., Ritz J., Basala M., Schlossman S.F. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res 1982, 42(2):457-464.
77. Kasten B.B., Liu T., Nedrow-Byers J.R., Benny P.D., Berkman C.E. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett 2013, 23(2):565-568.
78. Mukherjee A., Darlington T., Baldwin R., Holz C., Olson S., Kulkarni P., et al. Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. ChemMedChem 2014, 9:1356-1362.
79. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995, 84(4):493-498.
80. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83(5):761-769.
81. Schütz C.A., Juillerat-Jeanneret L., Mueller H., Lynch I., Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 2013, 8(3):449-467.
82. Fleuren E.D., Versleijen-Jonkers Y.M., Heskamp S., van Herpen C.M., Oyen W.J., van der Graaf W.T., et al. Theranostic applications of antibodies in oncology. Mol Oncol 2014, 8:799-812.
83. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338(6109):903-910.
84. Junghanns J.U., Muller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008, 3(3):295-309.
85. Junghanns J.U.A.H., Muller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008, 3(3):295-309.
86. Schutz C.A., Juillerat-Jeanneret L., Mueller H., Lynch I., Riediker M. Consortium N. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 2013, 8(3):449-467.
87. Bawa R. Nanoparticle-based therapeutics in humans: a survey. Nanotechnol Law Bus 2008, 5(2):135-155.
88. Martinez M.N., Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002, 42(6):620-643.
89. van't Klooster G., Hoeben E., Borghys H., Looszova A., Bouche M.P., van Velsen F., et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010, 54(5):2042-2050.
90. Spreen W., Min S., Ford S.L., Chen S., Lou Y., Bomar M., et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013, 14(5):192-203.
91. Pasut G., Veronese F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009, 61(13):1177-1188.
92. Karussis D., Teitelbaum D., Sicsic C., Brenner T., Grp A.M.-C.I.S. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010, 220(1-2):125-130.
93. Goldfine A.B., Fonseca V.A., Jones M.R., Wang A.C., Ford D.M., Truitt K.E. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010, 42(1):23-30.
94. Mease P.J. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatol (Oxf) 2011, 50(2):261-270.
95. Curran M.P., McCormack P.L. Methoxy polyethylene glycol-epoetin beta - a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008, 68(8):1139-1156.
96. Elzoghby A.O., Samy W.M., Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012, 157(2):168-182.
97. Bogner J.R., Kronawitter U., Rolinski B., Truebenbach K., Goebel F.D. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 1994, 7(5):463-468.
98. Slingerland M., Guchelaar H.J., Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012, 17(3-4):160-166.
99. Simon J.A. Group ES. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006, 13(2):222-231.
100. Jung C.W. Surface-properties of superparamagnetic iron-oxide Mr contrast agents - ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995, 13(5):675-691.
101. Petri-Fink A., Hofmann H. Superparamagnetic iron oxide nanoparticles (SPIONs): from synthesis to in vivo studies - a summary of the synthesis, characterization, in vitro, and in vivo investigations of SPIONs with particular focus on surface and colloidal properties. IEEE Trans Nanobiosci 2007, 6(4):289-297.
102. Herzog C., Hartmann K., Kunzi V., Kursteiner O., Mischler R., Lazar H., et al. Eleven years of Inflexal (R) V-a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27(33):4381-4387.
103. Bovier P.A. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008, 7(8):1141-1150.
104. van Kan-Davelaar H.E., van Hest J.C., Cornelissen J.J., Koay M.S. Using viruses as nanomedicines. Br J Pharmacol 2014, 171:4001-4009.
105. Rupp R., Rosenthal S.L., Stanberry L.R. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomed 2007, 2(4):561-566.
106. Johnston H., Brown D., Kermanizadeh A., Gubbins E., Stone V. Investigating the relationship between nanomaterial hazard and physicochemical properties: Informing the exploitation of nanomaterials within therapeutic and diagnostic applications. J Control Release 2012, 164(3):307-313.
107. Syed S., Zubair A., Frieri M. Immune response to nanomaterials: implications for medicine and literature review. Curr Allergy Asthma Rep 2013, 13(1):50-57.
108. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000564.jsp%26mid=WC0b01ac05806403e0.
109. Crist R.M., Grossman J.H., Patri A.K., Stern S.T., Dobrovolskaia M.A., Adiseshaiah P.P., et al. Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb) 2013, 5(1):66-73.
110. Dobrovolskaia M.A., Patri A.K., Simak J., Hall J.B., Semberova J., De Paoli Lacerda S.H., et al. Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm 2012, 9(3):382-393.
111. Dobrovolskaia M.A., Patri A.K., Potter T.M., Rodriguez J.C., Hall J.B., McNeil S.E. Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomed (Lond) 2012, 7(2):245-256.
112. Kobayashi H., Brechbiel M.W. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging 2003, 2(1):1-10.
113. Dobrovolskaia M.A., Neun B.W., Clogston J.D., Ding H., Ljubimova J., McNeil S.E. Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomed (Lond) 2010, 5(4):555-562.
114. Dobrovolskaia M.A., Neun B.W., Clogston J.D., Grossman J.H., McNeil S.E. Choice of method for endotoxin detection depends on nanoformulation. Nanomed (Lond) 2014, 9(12):1847-1856.
115. Ilinskaya A.N., Dobrovolskaia M.A. Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomed (Lond) 2013, 8(6):969-981.
116. Neun B.W., Dobrovolskaia M.A. Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Methods Mol Biol 2011, 697:121-130.
117. Vogel S.N. Lps: another piece in the puzzle. J Endotoxin Res 2000, 6(4):295-300. discussion 01-2.
118. Testing FPaE. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM310098.pdf.
119. Guidelines EE. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/12/WC500136403.pdf.
120. Dobrovolskaia M.A., Aggarwal P., Hall J.B., McNeil S.E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5(4):487-495.
121. Dobrovolskaia M.A., Germolec D.R., Weaver J.L. Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 2009, 4(7):411-414.
122. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2(8):469-478.
123. Gessner A., Lieske A., Paulke B.R., Muller R.H. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J Biomed Mater Res A 2003, 65(3):319-326.
124. Xu Y., Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003, 250(1):215-226.
125. Kivisakk P., Alm G.V., Fredrikson S., Link H. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 2000, 7(1):27-34.
126. Swanson S.J., Ferbas J., Mayeux P., Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004, 96(3):c88-95.
127. Chen B.X., Wilson S.R., Das M., Coughlin D.J., Erlanger B.F. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc Natl Acad Sci USA 1998, 95(18):10809-10813.
128. Braden B.C., Goldbaum F.A., Chen B.X., Kirschner A.N., Wilson S.R., Erlanger B.F. X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60). Proc Natl Acad Sci USA 2000, 97(22):12193-12197.
129. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 2007, 122(3):349-355.
130. Wang X., Ishida T., Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007, 119(2):236-244.
131. Stieneker F., Kreuter J., Lower J. High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS 1991, 5(4):431-435.
132. Dykman L.A., Sumaroka M.V., Staroverov S.A., Zaitseva I.S., Bogatyrev V.A. [Immunogenic properties of the colloidal gold]. Izv Akad Nauk Ser Biol 2004, 1:86-91.
133. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61(6):428-437.
134. http://ncl.cancer.gov/120406.pdf.
135. Tan Y., Li S., Pitt B.R., Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999, 10(13):2153-2161.
136. van Zijverden M., Granum B. Adjuvant activity of particulate pollutants in different mouse models. Toxicology 2000, 152(1-3):69-77.
137. Diwan M., Elamanchili P., Cao M., Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr Drug Deliv 2004, 1(4):405-412.
138. Lutsiak M.E., Kwon G.S., Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 2006, 58(6):739-747.
139. Chong C.S., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 2005, 102(1):85-99.
140. Cui Z., Mumper R.J. Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int J Pharm 2002, 238(1-2):229-239.
141. Cui Z., Patel J., Tuzova M., Ray P., Phillips R., Woodward J.G., et al. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 2004, 22(20):2631-2640.
142. Balenga N.A., Zahedifard F., Weiss R., Sarbolouki M.N., Thalhamer J., Rafati S. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J Biotechnol 2006, 124(3):602-614.
143. Rajananthanan P., Attard G.S., Sheikh N.A., Morrow W.J. Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice. Vaccine 1999, 18(1-2):140-152.
144. Caskey M., Lefebvre F., Filali-Mouhim A., Cameron M.J., Goulet J.P., Haddad E.K., et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 2011, 208(12):2357-2366.
145. Reddy S.T., Swartz M.A., Hubbell J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006, 27(12):573-579.
146. Rettig L., Haen S.P., Bittermann A.G., von Boehmer L., Curioni A., Kramer S.D., et al. Particle size and activation threshold: a new dimension of danger signaling. Blood 2010, 115(22):4533-4541.
147. Yang D., Zhao Y., Guo H., Li Y., Tewary P., Xing G., et al. [Gd@C(82)(OH)(22)](n) nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano 2010, 4(2):1178-1186.
148. Kanchan V., Panda A.K. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007, 28(35):5344-5357.
149. Lunov O., Syrovets T., Buchele B., Jiang X., Rocker C., Tron K., et al. The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials 2010, 31(19):5063-5071.
150. Zhu M.T., Wang B., Wang Y., Yuan L., Wang H.J., Wang M., et al. Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: risk factors for early atherosclerosis. Toxicol Lett 2011, 203(2):162-171.
151. Lucarelli M., Gatti A.M., Savarino G., Quattroni P., Martinelli L., Monari E., et al. Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. Eur Cytokine Netw 2004, 15(4):339-346.
152. Shaunak S., Thomas S., Gianasi E., Godwin A., Jones E., Teo I., et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004, 22(8):977-984.
153. Cromer J.R., Wood S.J., Miller K.A., Nguyen T., David S.A. Functionalized dendrimers as endotoxin sponges. Bioorg Med Chem Lett 2005, 15(5):1295-1298.
154. Chauhan A.S., Diwan P.V., Jain N.K., Tomalia D.A. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules 2009, 10(5):1195-1202.
155. Hirst S.M., Karakoti A.S., Tyler R.D., Sriranganathan N., Seal S., Reilly C.M. Anti-inflammatory properties of cerium oxide nanoparticles. Small 2009, 5(24):2848-2856.
156. Ahmad M.Z., Akhter S., Jain G.K., Rahman M., Pathan S.A., Ahmad F.J., et al. Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opin Drug Deliv 2010, 7(8):927-942.
157. Sumbayev V.V., Yasinska I.M., Garcia C.P., Gilliland D., Lall G.S., Gibbs B.F., et al. Gold nanoparticles downregulate interleukin-1beta-induced pro-inflammatory responses. Small 2013, 9(3):472-477.
158. Tsai C.Y., Lu S.L., Hu C.W., Yeh C.S., Lee G.B., Lei H.Y. Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J Immunol 2012, 188(1):68-76.
159. Mitchell L.A., Lauer F.T., Burchiel S.W., McDonald J.D. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat Nanotechnol 2009, 4(7):451-456.
160. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011, 63(12):1020-1030.
161. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003, 14(9):1430-1437.
162. Domanski D.M., Klajnert B., Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 2004, 63(1-2):189-191.
163. Bermejo J.F., Ortega P., Chonco L., Eritja R., Samaniego R., Mullner M., et al. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry 2007, 13(2):483-495.
164. Agashe H.B., Babbar A.K., Jain S., Sharma R.K., Mishra A.K., Asthana A., et al. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers. Nanomed (Lond) 2007, 3(2):120-127.
165. Shah D.S., Sakthivel T., Toth I., Florence A.T., Wilderspin A.F. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm 2000, 208(1-2):41-48.
166. Radomski A., Jurasz P., Alonso-Escolano D., Drews M., Morandi M., Malinski T., et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005, 146(6):882-893.
167. Ilinskaya A.N., Dobrovolskaia M.A. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomed (Lond) 2013, 8(5):773-784.
168. Zhu M.T., Feng W.Y., Wang B., Wang T.C., Gu Y.Q., Wang M., et al. Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats. Toxicology 2008, 247(2-3):102-111.
169. http://www.etp-nanomedicine.eu/public/about/.
170. http://nano.gov/sites/default/files/medicine_-_loubaton.pdf.
171. http://www.cancer.gov/.
172. NCL, 2014. http://ncl.cancer.gov/.
173. ETP, 2013. http://www.etp-nanomedicine.eu/public/press-documents/publications/etp-documents/supporting-documents-for-etpn-white-paper-2013/European%20NCL%20Factsheet%20Final.pdf.
174. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4(128):128ra39.
175. Shi J., Xiao Z., Kamaly N., Farokhzad O.C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011, 44(10):1123-1134.
176. Therapeutics B, 2014, http://www.bindtherapeutics.com/index.html.
177. Thill M., Kurylcio A., Welter R., van Haasteren V., Grosse B., Berclaz G., et al. The Central-European SentiMag study: Sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast 2014, 23:175-179.
178. Markman J.L., Rekechenetskiy A., Holler E., Ljubimova J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013, 65(13-14):1866-1879.
179. Barkalina N., Charalambous C., Jones C. Nanotechnology in reproductive medicine: emerging applications of nanomaterials. Nanomed Nanotechnol Biol Med 2014, 10:921-938.
180. Schiener M., Hossann M., Viola J.R., Ortega-Gomez A., Weber C., Lauber K., et al. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Mol Med 2014, 20(5):271-281.
181. Gaucher G., Satturwar P., Jones M.-C., Furtos A., Leroux J.-C. Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm 2010, 76(2):147-158.
182. Bromberg L. Polymeric micelles in oral chemotherapy. J Control Release 2008, 128(2):99-112.
183. Pepić I., Lovrić J., Filipović-Grčić J. How do polymeric micelles cross epithelial barriers?. Eur J Pharm Sci 2013, 50(1):42-55.
184. Mei L., Zhang Z., Zhao L., Huang L., Yang X.-L., Tang J., et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev 2013, 65(6):880-890.
185. Radha S. Medical application of nanotechnology in nanomedicine. J Sci 2013, 3(1):28-34.
186. Fischer S. Regulating Nanomedicine: new nano tools offer great promise for the future-if regulators can solve the difficulties that hold development back. Pulse IEEE 2014, 5(2):21-24.
187. http://www.mhra.gov.uk/index.htm#page=DynamicListMedicines.
188. http://www.mhra.gov.uk/home/groups/dts-bi/documents/websiteresources/con2025205.pdf.
189. http://www.ema.europa.eu/ema/pdfs/human/genetherapy/7976906en.pdf.
190. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2010/09/WC500096201.pdf.
191. Guidance for Industry: safety of nanomaterials in cosmetic products 2014, FDA.
192. http://www.clinam.org/.
193. http://www.esnam.org/.
194. http://www.britishsocietynanomedicine.org.
195. http://www.sfnano.fr.
196. http://www.nano-med.cz/.
197. http://www.nanomedspain.net/.
198. http://amsocnanomed.org/.
199. http://www.innam.org/.
200. http://www.sintef.no/Projectweb/Nanomedicine.
201. http://www.nanodermsociety.org/.
202. Nasir A., Friedman A. Nanotechnology and the Nanodermatology Society. J Drugs Dermatol 2010, 9(7):879-882.
203. Chow S.-C., Liu J.-P. Design and analysis of clinical trials: concepts and methodologies 2013, John Wiley & Sons.
204. http://clinicaltrials.gov/show/NCT00108745.
205. Vandegriff K.D., Winslow R.M. Hemospan: design principles for a new class of oxygen therapeutic. Artif Organs 2009, 33(2):133-138.
206. Booser D., Esteva F., Rivera E., Valero V., Esparza-Guerra L., Priebe W., et al. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 2002, 50(1):6-8.
207. Wetzler M., Thomas D.A., Wang E.S., Shepard R., Ford L.A., Heffner T.L., et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leukemia 2013, 13(4):430-434.
208. Löwenberg M., Verhaar A., van den Blink B., ten Kate F., van Deventer S., Peppelenbosch M., et al. Specific inhibition of c-Raf activity by semapimod induces clinical Remission in severe Crohn's disease. J Immunol 2005, 175(4):2293-2300.
209. Bomalaski J.S., Holtsberg F.W., Ensor C.M., Clark M.A. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002, 29(9):1942-1949.
210. Lee S.-W., Yun M.-H., Jeong S.W., In C.-H., Kim J.-Y., Seo M.-H., et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J Control Release 2011, 155(2):262-271.
211. Ranade A.A., Joshi D.A., Phadke G.K., Patil P.P., Kasbekar R.B., Apte T.G., et al. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol 2013, 24(Suppl. 5):v6-v12.
212. Schütz C.A., Juillerat-Jeanneret L., Soltmann C., Mueller H. Toxicity data of therapeutic nanoparticles in patent documents. World Pat Inf 2013, 35(2):110-114.
213. van der Meel R., Vehmeijer L.J.C., Kok R.J., Storm G., van Gaal E.V.B. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 2013, 65(10):1284-1298.
214. Iyer A.K., Singh A., Ganta S., Amiji M.M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013, 65(13-14):1784-1802.
215. Muthu M.S., Leong D.T., Mei L., Feng S.S. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4(6):660-677.
216. Kievit F.M., Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res 2011, 44(10):853-862.
217. Chen W.H., Xu X.D., Jia H.Z., Lei Q., Luo G.F., Cheng S.X., et al. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials 2013, 34(34):8798-8807.